Cargando…
COVID‐19 and dexamethasone‐induced hyperglycaemia: Workload implications for diabetes inpatient teams
Autores principales: | Younes, Younes R., Stockley, Susan, Keegan, Lorna, O’Donoghue, Linda, Yohannan, Elizabeth, Read, Liz, Williamson, Jamie‐Leigh, Peter, John, Lakshmipathy, Kavitha, Smout, Vera, Nayyar, Vidhu, Emmanuel, Julian, Zachariah, Sunil, Clark, James, Field, Benjamin C. T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8646374/ https://www.ncbi.nlm.nih.gov/pubmed/34651335 http://dx.doi.org/10.1111/dme.14716 |
Ejemplares similares
-
Dexamethasone: Sinonasal mucormycosis and hyperglycaemia: case report
Publicado: (2021) -
Dexamethasone: Hyperglycaemia and adrenal insufficiency: 2 case reports
Publicado: (2021) -
Dexamethasone-induced hyperglycaemia in COVID-19: Glycaemic profile in patients without diabetes and factors associated with hyperglycaemia
por: Rhou, Yoon Ji J, et al.
Publicado: (2022) -
Dexamethasone: Hyperglycaemia following off-label use: case report
Publicado: (2022) -
Ceftriaxone/dexamethasone/immune-globulin: Hyperglycaemia and Off-label-use: case report
Publicado: (2021)